You can buy or sell EDAP TMS and other stocks, options, ETFs, and crypto commission-free!
EDAP TMS SA develops, produces and markets minimally invasive medical devices for urological diseases. HIFU treatment is shown to be a minimally invasive and effective treatment option with a low occurrence of side effects. Read More Ablatherm-HIFU is generally recommended for patients with localized prostate cancer who are not candidates for surgery or who prefer an alternative option, or for patients who failed radiotherapy treatment, Ablatherm-HIFU is approved and commercialized in Europe as a treatment for prostate cancer and is currently under regulatory review in the U.S. In March 2013, the company introduced a new innovative HIFU device, the Focal One dedicated to focal therapy of prostate cancer. The company was founded on December 3, 1979 and is headquartered in Vaulx-en-Velin, France.
52 Week High
52 Week Low
Simply Wall StMar 8
Did Changing Sentiment Drive EDAP TMS’s Share Price Down By 34%?
While not a mind-blowing move, it is good to see that the EDAP TMS S.A. (NASDAQ:EDAP) share price has gained 10% in the last three months.
Associated PressMar 4
EDAP TMS SA : HIFU Pioneer Houston Methodist Hospital Acquires EDAP’s Next Generation Focal One HIFU System
Houston Methodist’s Upgrade from Ablatherm to Focal One Reinforces EDAP’s Position as a Leading HIFU Innovator LYON, France, March 4, 2019 -- EDAP TMS SA (Nasdaq: EDAP) -- Houston Methodist Hospital, one of the first hospitals in the U.S. to offer Ablatherm® Robotic High Intensity Focused Ultrasound (HIFU) for patients with localized prostate cancer, has acquired Focal One®, the most advanced HIFU technology available today. Houston Methodist Hospital initially invested in EDAP’s first generation HIFU sys...
Expected Mar 26, After Hours